Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Real-world Application and Practical Considerations for Clinical Practice

<i>Background:</i> Ozanimod, a selective sphingosine-1-phosphate (S1P) receptor modulator, represents the first-in-class oral small molecule therapy approved for ulcerative colitis (UC), marking a paradigm shift in inflammatory bowel disease (IBD) management. <i>Objective:</i> To comprehensively review ozanimod therapy in IBD, evaluating its mechanism of action, clinical efficacy, safety profile, real-world experience, and practical implementation considerations through systematic analysis of available evidence. <i>Methods:</i> A systematic literature review was conducted using verified clinical trial data, observational studies, and regulatory documents from January 2016 to August 2025. Studies included randomized controlled trials, real-world evidence publications, safety analyses, and mechanistic studies. Key search terms included "ozanimod," "S1P receptor modulator," "ulcerative colitis," "Crohn's disease," and "inflammatory bowel disease." <i>Results:</i> Analysis of clinical trials revealed that ozanimod demonstrated significant efficacy in phase 3 UC trials, with clinical remission rates of 18.4% versus 6.0% (placebo) at week 10 and 37.0% versus 18.5% at week 52. Advanced therapy-naive patients showed enhanced responses (56% vs 39% symptomatic response by week 2). Real-world studies confirmed effectiveness in treatment-refractory populations with clinical response rates of 44-58% at week 10. The safety profile was favorable with predictable adverse events and no new safety signals in long-term follow-up. <i>Conclusions:</i> Ozanimod represents a significant advancement in IBD therapy, offering an oral, well-tolerated treatment option with unique mechanism of action. Enhanced efficacy in treatment-naive patients supports early positioning in treatment algorithms before biologics.